The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Knocking down barriers: advances in siRNA delivery
Open accessAbstract
In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, there has been an exponential growth in the development of clinically suitable nonviral delivery systems for siRNA (19,20); we have taken advantage of these innovations to develop the LNP/RNA formulation and have now embarked on a more extensive evaluation of other nonviral delivery systems.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are limited published data on the in vivo delivery of self-amplifying RNA using nonviral delivery strategies (3,14,18), and none has taken advantage of the recently developed, clinically suitable delivery systems for siRNA (19,20).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [20]
In the citing paper
“Additionally, endosomal membranes have been damaged or rebuilt using cell penetrating peptides to enhance the intracellular delivery of nucleic acids.313”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [313]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 5,018
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., RINGOLD, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,954
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,004
Progress in material design for biomedical applications
Tibbitt, M. W., Rodell, C. B., Burdick, J. A., & Anseth, K. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516247112 · Cited by 244
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Conde, J., Bao, C., Tan, Y., Cui, D., Edelman, E. R., Azevedo, H. S., Byrne, H. J., Artzi, N., & Tian, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501283 · Cited by 242
Ashley, C. E., Carnes, E. C., Epler, K. E., Padilla, D. P., Phillips, G. K., Castillo, R., Wilkinson, D., Wilkinson, B., Burgard, C., Kalinich, R. M., et al. (2012) · ACS Nano · doi:10.1021/nn204102q · Cited by 243
Farjadian, F., Roointan, A., Mohammadi‐Samani, S., & Hosseini, M. H. (2018) · Chemical Engineering Journal · doi:10.1016/j.cej.2018.11.156 · Cited by 248
Enhanced Endosomal Escape by Light-Fueled Liquid-Metal Transformer
Lü, Y., Lin, Y., Chen, Z., Hu, Q., Liu, Y., Yu, S., Gao, W., Dickey, M. D., & Gu, Z. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04346 · Cited by 241
Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments
Karlsson, J. E., Vaughan, H. J., & Green, J. J. (2018) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060817-084055 · Cited by 244
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
Xu, L., Chen, Y., Wang, M., Ma, Y., Xia, W., & Gu, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.072 · Cited by 245
Yu, H., Zou, Y., Wang, Y., Huang, X., Huang, G., Sumer, B. D., Boothman, D. A., & Gao, J. (2011) · ACS Nano · doi:10.1021/nn203503h · Cited by 239
Tumor-targeting multi-functional nanoparticles for theragnosis: New paradigm for cancer therapy
Ryu, J. H., Koo, H., Sun, I., Yuk, S. H., Choi, K., Kim, K., & Kwon, I. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.012 · Cited by 237
Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
Draz, M. S., Fang, B. A., Zhang, P., Hu, Z., Gu, S., Weng, K. C., Gray, J. W., & Chen, F. F. (2014) · Theranostics · doi:10.7150/thno.9404 · Cited by 242
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy
Zhou, J., & Rossi, J. J. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.21 · Cited by 238
Lipidoid-Coated Iron Oxide Nanoparticles for Efficient DNA and siRNA delivery
Jiang, S., Eltoukhy, A. A., Love, K. T., Langer, R., & Anderson, D. G. (2013) · Nano Letters · doi:10.1021/nl304287a · Cited by 239
Self-citationRecent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors
Wang, H., Jiang, Y., Peng, H., Chen, Y., Zhu, P., & Huang, Y. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.031 · Cited by 235
Zhu, S., Ma, L., Wang, S., Chen, C., Zhang, W., Yang, L., Hang, W., Nolan, J. P., Wu, L., & Yan, X. (2014) · ACS Nano · doi:10.1021/nn505162u · Cited by 232
The safety of Covid-19 mRNA vaccines: a review
Anand, P., & Stahel, V. P. (2021) · Patient Safety in Surgery · doi:10.1186/s13037-021-00291-9 · Cited by 239
A Phenylboronate‐Functionalized Polyion Complex Micelle for ATP‐Triggered Release of siRNA
Naito, M., Ishii, T., Matsumoto, A., Miyata, K., Miyahara, Y., & Kataoka, K. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203360 · Cited by 232
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
pH-Responsive Polymeric Micelle Carriers for siRNA Drugs
Convertine, A. J., Diab, C., Prieve, M. G., Paschal, A. E., Hoffman, A. S., Johnson, P. H., & Stayton, P. S. (2010) · Biomacromolecules · doi:10.1021/bm100652w · Cited by 230
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems
Badea, I., & Kaur, R. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s37348 · Cited by 229
Álvarez‐Benedicto, E., Farbiak, L., Ramírez, M. M., Wang, X., Johnson, L. T., Mian, O. T., Guerrero, E. D., & Siegwart, D. J. (2021) · Biomaterials Science · doi:10.1039/d1bm01454d · Cited by 235
Expert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 232
A Crosslinked Nucleic Acid Nanogel for Effective siRNA Delivery and Antitumor Therapy
Ding, F., Mou, Q., Ma, Y., Pan, G., Guo, Y., Tong, G., Choi, C. H. J., Zhu, X., & Zhang, C. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711242 · Cited by 227
Theranostic nanoparticles for future personalized medicine
Ryu, J. H., Lee, S., Son, S., Kim, S. H., Leary, J. F., Choi, K., & Kwon, I. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.027 · Cited by 230
A Tubular DNA Nanodevice as a siRNA/Chemo‐Drug Co‐delivery Vehicle for Combined Cancer Therapy
Wang, Z., Song, L., Liu, Q. L., Tian, R., Shang, Y., Liu, F., Liu, S., Zhao, S., Han, Z., Sun, J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202009842 · Cited by 223
Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA
Singh, S. P., Narang, A. S., & Mahato, R. I. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0608-1 · Cited by 228
Delivery systems for siRNA drug development in cancer therapy
Xu, C., & Wang, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.08.011 · Cited by 232
Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lü, C., Bottsford-Miller, J. N., Nishimura, M., Mora, E., Lee, J., Stone, R. L., Pecot, C. V., et al. (2011) · Neoplasia · doi:10.1593/neo.101372 · Cited by 221
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A. K., Fitzgerald, K. J., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 232
Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy
Guo, S., & Huang, L. (2011) · Journal of Nanomaterials · doi:10.1155/2011/742895 · Cited by 224
Current Development of siRNA Bioconjugates: From Research to the Clinic
Chernikov, I. V., Vlassov, V. V., & Chernolovskaya, E. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00444 · Cited by 221
Cell-penetrating Peptides as Versatile Vehicles for Oligonucleotide Delivery
Margus, H., Padari, K., & Pooga, M. (2012) · Molecular Therapy · doi:10.1038/mt.2011.284 · Cited by 218
Lipid nanoparticles for siRNA delivery in cancer treatment
Moukhtari, S. H. E., Garbayo, E., Amundarain, A., Pascual‐Gil, S., Carrasco‐Leon, A., Prósper, F., Agirre, X., & Blanco‐Prieto, M. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.054 · Cited by 221
Wang, Q., Jiang, H., Li, Y., Chen, W., Li, H., Peng, K., Zhang, Z., & Sun, X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.008 · Cited by 216
Liposomal Spherical Nucleic Acids
Banga, R. J., Chernyak, N., Narayan, S. P., Nguyen, S. T., & Mirkin, C. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504845f · Cited by 213
Dong, Y., Yu, T., Ding, L., Laurini, E., Huang, Y., Zhang, M., Weng, Y., Lin, S., Chen, P., Marson, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10021 · Cited by 221
A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes
Ramishetti, S., Hazan‐Halevy, I., Palakuri, R., Chatterjee, S., Naidu, G. S., Dammes, N., Freilich, I., Shmuel, L. K., Danino, D., & Peer, D. (2020) · Advanced Materials · doi:10.1002/adma.201906128 · Cited by 220
Multistage Nanovectors: From Concept to Novel Imaging Contrast Agents and Therapeutics
Godin, B., Tasciotti, E., Liu, X., Serda, R. E., & Mauro Ferrari, B. (2011) · Accounts of Chemical Research · doi:10.1021/ar200077p · Cited by 213
Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 212
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
Shukla, S., Sumaria, C. S., & Pradeepkumar, P. I. (2009) · ChemMedChem · doi:10.1002/cmdc.200900444 · Cited by 212
Gujrati, M. D., Malamas, A. S., Shin, T., Jin, E., Sun, Y., & Lu, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400787s · Cited by 216
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy
Xu, X., Wu, J., Liu, Y., Saw, P. E., Tao, W., Yu, M., Zope, H. R., Si, M., Victorious, A. P., Rasmussen, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b07195 · Cited by 207
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K., Burnett, J., & Rossi, J. J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 211
Liu, X., Zhou, J., Yu, T., Chen, C., Cheng, Q., Sengupta, K., Huang, Y., Li, H., Liu, C., Wang, Y., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406764 · Cited by 206
RetractedYang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
Enhancing endosomal escape for nanoparticle mediated siRNA delivery
Ma, D. (2014) · Nanoscale · doi:10.1039/c4nr00018h · Cited by 205
Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors
Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202
Sequence-non-specific effects of RNA interference triggers and microRNA regulators
Olejniczak, M., Galka-Marciniak, P., & Krzyżosiak, W. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp829 · Cited by 204
Yin, F., Hu, K., Chen, Y., Yu, M., Wang, D., Wang, Q., Yong, K., Lu, F., Liang, Y., & Li, Z. (2017) · Theranostics · doi:10.7150/thno.17841 · Cited by 201
Zhu, X., Xu, Y., Solis, L. M., Wei, T., Wang, L., Behrens, C., Xu, X., Zhao, L., Liu, D. X., Wu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505629112 · Cited by 200
A Tailored DNA Nanoplatform for Synergistic RNAi‐/Chemotherapy of Multidrug‐Resistant Tumors
Liu, J., Song, L., Liu, S., Zhao, S., Jiang, Q., & Ding, B. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201809452 · Cited by 201
Myc proteins as therapeutic targets
Gustafson, W. C., & Weiss, W. A. (2010) · Oncogene · doi:10.1038/onc.2009.512 · Cited by 204
Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery
Biswas, S., Deshpande, P. P., Navarro, G., Dodwadkar, N. S., & Torchilin, V. P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.024 · Cited by 197
Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404629 · Cited by 198
Upconversion Nanoparticle-Based FRET System for Study of siRNA in Live Cells
Jiang, S., & Zhang, Y. (2010) · Langmuir · doi:10.1021/la904011q · Cited by 199
Grimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
Shi, J., Xiao, Z., Votruba, A. R., Vilos, C., & Farokhzad, O. C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101554 · Cited by 195
Xiao, B., Laroui, H., Ayyadurai, S., Viennois, É., Charania, M. A., Zhang, Y., & Merlin, D. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.008 · Cited by 194
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice
Godin, B., Chiappini, C., Srinivasan, S., Alexander, J. F., Yokoi, K., Mauro Ferrari, B., Decuzzi, P., & Liu, X. (2012) · Advanced Functional Materials · doi:10.1002/adfm.201200869 · Cited by 194
Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery
Siegwart, D. J., Whitehead, K. A., Nuhn, L., Sahay, G., Cheng, H., Jiang, S., Ma, M., Lytton‐Jean, A. K. R., Vegas, A. J., Fenton, P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106379108 · Cited by 193
Self-citationTargeted Polymeric Micelles for siRNA Treatment of Experimental Cancer by Intravenous Injection
Christie, R. J., Matsumoto, Y., Miyata, K., Nomoto, T., Fukushima, S., Osada, K., Halnaut, J., Pittella, F., Kim, H. J., Nishiyama, N., et al. (2012) · ACS Nano · doi:10.1021/nn300942b · Cited by 193
Targeting breast cancer stem cells
McDermott, S., & Wicha, M. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.005 · Cited by 198
Poly(β‐Amino Esters): Synthesis, Formulations, and Their Biomedical Applications
Liu, Y., Li, Y., Keskin, D., & Shi, L. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801359 · Cited by 192
Smart chemistry in polymeric nanomedicine
Tong, R., Tang, L., Ma, L., Tu, C., Baumgartner, R., & Cheng, J. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00133h · Cited by 195
Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA
Jensen, D. K., Jensen, L., Koocheki, S., Bengtson, L., Cun, D., Nielsen, H. M., & Foged, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.011 · Cited by 190
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer
Li, Q., Qin, T., Bi, Z., Hong, H., Ding, L., Chen, J., Wu, W., Lin, X., Fu, W., Zheng, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15308-7 · Cited by 192
Xue, L., Gong, N., Shepherd, S. J., Xiong, X., Liao, X., Han, X., Zhao, G., Song, C., Huang, X., Zhang, H., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02706 · Cited by 191
Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery
Alabi, C. A., Love, K. T., Sahay, G., Yin, H., Luly, K. M., Langer, R., & Anderson, D. G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306529110 · Cited by 188
Self-citationNanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies
Ediriwickrema, A., & Saltzman, W. M. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/ab500084g · Cited by 193
Computational models for lncRNA function prediction and functional similarity calculation
Chen, X., Sun, Y., Guan, N., Qu, J., Huang, Z.-A., Zhu, Z., & Li, J. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely031 · Cited by 190
The packaging of siRNA within the mesoporous structure of silica nanoparticles
Xu, L., Xie, Q. R., Zhang, J., Xia, W., & Gu, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.068 · Cited by 193
Bost, J., Barriga, H. M. G., Holme, M. N., Gallud, A., Maugeri, M., Gupta, D., Lehto, T., Valadi, H., Esbjörner, E. K., Stevens, M. M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c05099 · Cited by 189
Small silencing RNAs: State-of-the-art
Grimm, D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.002 · Cited by 191
Zhang, J., Chen, B., Gan, C., Sun, H., Zhang, J., & Feng, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s436038 · Cited by 190
Glutathione-mediated nanomedicines for cancer diagnosis and therapy
Ding, Y., Dai, Y., Wu, M., & Li, L. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.128880 · Cited by 186
Zhou, K., Nguyen, L. H., Miller, J. B., Yan, Y., Kós, P., Xiong, H., Li, L., Hao, J., Minnig, J. T., Zhu, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520756113 · Cited by 185
Omid Veiseh, A., Kievit, F. M., Fang, C., Mu, N., Jana, S., Leung, M. C., Mok, H., Ellenbogen, R. G., Park, J. O., & Zhang, M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.016 · Cited by 183
Genetic modifications of pigs for medicine and agriculture
Whyte, J. J., & Prather, R. S. (2011) · Molecular Reproduction and Development · doi:10.1002/mrd.21333 · Cited by 186
Basha, G., Novobrantseva, T. I., Rosin, N. L., Tam, Y. Y. C., Hafez, I. M., Wong, M., Sugo, T., Ruda, V. M., Qin, J., Klebanov, B., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.190 · Cited by 182
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.006 · Cited by 185
An influenza virus-inspired polymer system for the timed release of siRNA
Truong, N. P., Gu, W., Prasadam, I., Jia, Z., Crawford, R., Xiao, Y., & Monteiro, M. J. (2013) · Nature Communications · doi:10.1038/ncomms2905 · Cited by 180
Polyvalent Nucleic Acid Nanostructures
Cutler, J. I., Zhang, K., Zheng, D., Auyeung, E., Prigodich, A. E., & Mirkin, C. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203375n · Cited by 185
Efficient Functional Delivery of siRNA using Mesoporous Silica Nanoparticles with Ultralarge Pores
Na, H., Kim, M., Park, K., Ryoo, S., Lee, K. E., Jeon, H., Ryoo, R., Hyeon, C., & Min, D. (2012) · Small · doi:10.1002/smll.201200028 · Cited by 183
Yang, W. M., Liu, S., Bai, T., Keefe, A. J., Zhang, L., Ella‐Menye, J., Li, Y., & Jiang, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.02.004 · Cited by 186
Amjad, M. W., Kesharwani, P., Amin, M. C. I. M., & Iyer, A. K. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.09.008 · Cited by 179
Exosomes as Drug Carriers for Cancer Therapy
Pullan, J. E., Confeld, M. I., Osborn, J., Kim, J., Sarkar, K., & Mallik, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00104 · Cited by 179
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Application of Nanotechnology in Drug Delivery
Silva, J., Fernandes, A. R., & Baptista, P. V. (2014) · InTech eBooks · doi:10.5772/58424 · Cited by 181
The Role of Hypoxia-Induced miR-210 in Cancer Progression
Dang, K., & Myers, K. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036353 · Cited by 181
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 180
The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Dua, K., Wadhwa, R., Singhvi, G., Rapalli, V. K., Shukla, S. D., Shastri, M. D., Gupta, G., Satija, S., Mehta, M., Khurana, N., et al. (2019) · Drug Development Research · doi:10.1002/ddr.21571 · Cited by 178
Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma
Siu, K. S., Chen, D., Zheng, X., Zhang, X., Johnston, N., Liu, Y., Yuan, K., Koropatnick, J. D., Gillies, E. R., & Min, W.-P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.079 · Cited by 176
Cellular processing and destinies of artificial DNA nanostructures
Lee, D. S., Qian, H., Tay, C. Y., & Leong, D. T. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00700c · Cited by 179
Zhang, R., Ahmed, T., Li, L. Y., Li, J., Abbasi, A. Z., & Wu, X. Y. (2016) · Nanoscale · doi:10.1039/c6nr08486a · Cited by 180
Journey of siRNA: Clinical Developments and Targeted Delivery
Nikam, R. R., & Gore, K. R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0715 · Cited by 175
Metadata
- Authors
- Whitehead, K. A., Langer, R., & Anderson, D. G.
- Affiliations
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Corresponding author
- Anderson, Daniel G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-02
- Volume
- 8
- Issue
- 2
- Pages
- 129-138
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC7097568
- OpenAlex
- W1964146045
- Cited by
- 3,115
- References
- 106
- Citations by year
- 2026: 96 · 2025: 114 · 2024: 150 · 2023: 120 · 2022: 159 · 2021: 207 · 2020: 148 · 2019: 191 · 2018: 183 · 2017: 199 · 2016: 220 · 2015: 218 · 2014: 240 · 2013: 233 · 2012: 222
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- siRNA delivery, RNA interference therapy, gene silencing, nucleic acid encapsulation, intracellular delivery, age-related macular degeneration, respiratory syncytial virus, clinical trials
- MeSH terms
- Animals, Clinical Trials as Topic, Humans, Liposomes, Drug Delivery Systems, RNA Interference, RNA, Small Interfering, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
